Columbia Interventional Cardiology Performs First Commercial Use of Emboliner System in Transcatheter Heart Procedures
The device captures and removes embolic material during transcatheter aortic valve replacement (TAVR).
Columbia interventional cardiologist Tamim Nazif, MD, led the first commercial use of the Emboliner system, an embolic protection device that captures and removes embolic material during transcatheter aortic valve replacement (TAVR).
“The Emboliner provides complete embolic protection by covering the entirety of the aortic arch, capturing any debris and protecting all three vessels to the brain, as well as the descending aorta,” says Dr. Nazif, co-director of the Structural Heart and Valve Center at NewYork-Presbyterian and Columbia. “It provides more comprehensive protection than currently exists.”
TAVR was developed as a nonsurgical alternative to aortic valve replacement surgery for aortic stenosis. Using a catheter to access the heart through a large blood vessel, wires are used to guide the artificial valve to the heart, where the device is then implanted directly into the calcified aortic valve.
During the TAVR procedure, pieces from the calcified heart valve, blood clots, or other debris can break loose and travel through the arteries toward the brain. This embolic debris may restrict or block blood flow to the brain or other organs, leading to serious and potentially life-threatening ischemic events like stroke.
The Emboliner device uses a cylindrical mesh filter that covers the entire aortic arch, providing full protection from embolic debris. Its expanding access port allows the TAVR device and other equipment to pass through without compromising the filter's effectiveness.
Dr. Nazif served as Co-Principal Investigator of the PROTECT H2H study, a prospective, randomized, multicenter study to demonstrate safety and effectiveness. This study included 500 participants at 20 centers worldwide and helped drive regulatory clearance of the Emboliner in the United States.
The FDA provided 510(k) clearance for the Emboliner in September 2026, and it is currently indicated for use during TAVR. Dr. Nazif sees potential uses for the Emboliner beyond TAVR. “
We have a lot of other patients who need relatively higher-risk structural heart procedures, including for the mitral valve, who could benefit from this,” says Dr. Nazif. “We’re looking into doing additional studies on these types of cases that go beyond the current approval.”
Related